Drugs / Anti-GD2 CART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02765243 | Jan 2016 → Jan 2019 | neuroblastoma | Zhujiang Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-GD2 CART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02765243 ↗ |
| Known as | 4SCAR-GD2 | “The investigators are attempt to treat this disease using T cells genetically modified with a 4th generation lentiviral chimeric antigen receptor (CAR) targeting GD2 (4SCAR-GD2).” NCT02765243 ↗ |
| Action | Deplete | “4SCAR-GD2-modified T cells can recognize and kill neuroblastoma through the recognition of GD2” NCT02765243 ↗ |
| Modality | Cell therapy | “T cells genetically modified with a 4th generation lentiviral chimeric antigen receptor (CAR)” NCT02765243 ↗ |